BULLFROG AI HOLDINGS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
BULLFROG AI HOLDINGS, INC. (BFRG) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $378.23 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-11-14
- BULLFROG AI HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $378.23K, a 87.64% increase year-over-year.
- BULLFROG AI HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $177.91K, a 7.53% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $300.29K, a 10.47% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $201.57K, a 65.96% increase year-over-year.
- BULLFROG AI HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $943.65K, a 49.42% increase from fiscal 2023.
- BULLFROG AI HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $631.53K, a 85.66% increase from fiscal 2022.
- BULLFROG AI HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $340.15K, a 3524.42% increase from fiscal 2021.
- BULLFROG AI HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $9.38K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-09-30 | $378.23K 10-Q · filed 2025-11-14 | $556.13K derived: sum of 2 quarters · filed 2025-11-14 | $856.42K derived: sum of 3 quarters · filed 2025-11-14 | |
| 2025-06-30 | $177.91K 10-Q · filed 2025-11-14 | $478.19K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2025-03-31 | $300.29K 10-Q · filed 2025-11-14 | |||
| 2024-12-31 | $943.65K 10-K · filed 2025-03-14 | |||
| 2024-09-30 | $201.57K 10-Q · filed 2025-11-14 | $393.95K derived: sum of 2 quarters · filed 2025-11-14 | $729.37K derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $192.38K 10-Q · filed 2025-11-14 | $527.80K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $335.42K 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $631.53K 10-K · filed 2025-03-14 | |||
| 2023-09-30 | $121.46K 10-Q · filed 2024-11-08 | $383.73K derived: sum of 2 quarters · filed 2024-11-08 | $511.18K derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-06-30 | $262.27K 10-Q · filed 2024-11-08 | $389.72K derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-03-31 | $127.45K 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $340.15K 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $51.54K 10-Q · filed 2023-11-14 | $260.86K derived: sum of 2 quarters · filed 2023-11-14 | $290.88K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $209.32K 10-Q · filed 2023-11-14 | $239.34K derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $30.02K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $9.38K 10-K · filed 2023-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B |